Emopamil's structure consists of an organic
amino compound,
nitrile compound and a member of two
benzene rings.
Applications
Emopamil also known as EMP is a
phenylalkylamine and inhibitor of
5-hydroxytryptamine 5-HT2 receptors.[2] EMP includes a chiral quaternary carbon center, and research has indicated that its
optical isomers have different biological effects.[3] It interacts in an extracellular site of the
nerve cell to inhibit calcium channel responses while other phenylalkylamines act at an intracellular site. The interaction site of emopamil suggests to its greater neuroprotective efficacy in research related to
ischaemia.[4]
^Paul, Raymond; Silve, Sandra; De Nys, Nathalie; Dupuy, Pascal-Henry; Labit-Le Bouteiller, Christine; Rosenfeld, Jorge; Ferrara, Pascual; Le Fur, Gérard; Casellas, Pierre; Loison, Gérard (1998). "Both the Immunosuppressant SR31747 and the Antiestrogen Tamoxifen Bind to an Emopamil-Insensitive Site of Mammalian Δ8-Δ7 Sterol Isomerase". Journal of Pharmacology and Experimental Therapeutics. 285 (3): 1296–302.
PMID9618436.
^Toyohara, J.; Okamoto, M.; Aramaki, H.; Zaitsu, Y.; Shimizu, I.; Ishiwata, K. (2016). "(R)-¹¹CEmopamil as a novel tracer for imaging enhanced P-glycoprotein function". Nuclear Medicine and Biology. 43 (1): 52–62.
doi:
10.1016/j.nucmedbio.2015.09.001.
PMID26429767.